Recent advances in the chemotherapy of leishmaniases;Recenti sviluppi nella terapia delle leishmaniosi

Annali dell'Istituto Superiore di Sanita

Volumn 37, Issue 2, 2001, Pages 255-263

  Gradoni, L ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Leishmania; Leishmaniasis; Therapy

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; ATOVAQUONE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MILTEFOSINE; PENTAMIDINE ISETHIONATE; RECOMBINANT GAMMA INTERFERON;

DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG TOXICITY; ENDEMIC DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEISHMANIA; LEISHMANIASIS; NAUSEA AND VOMITING; REVIEW;

HUMANS; LEISHMANIASIS;

EID: 0035155239     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Control of the leishmaniases
2. Le leishmaniosi del Vecchio Mondo
3. Leishmaniasis: Public health aspects and control
4. Recrudescence of visceral leishmaniasis unrelated to HIV infection in the Campania region of Italy
5. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy
6. Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy
7. Heterogeneity among zymodemes of Leishmania infantum from HIV-positive patients with visceral leishmaniasis in south Italy
8. New perspectives on a subclinical form of visceral leishmaniasis
9. Age, acquired immunity and the risk of visceral leishmaniasis: A prospective study in Iran
10. Outbreak of kala-azar in the Sudan
11. Outbreak of kala-azar in Bombay
12. Un caso di Post Kala-Azar Dermal Leishmaniasis nell'area del Mediterraneo
13. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm
14. T-cell response in human leishmaniasis
15. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis
16. Treatment of Mediterranean visceral leishmaniasis
17. Chemotherapy of leishmaniasis and trypanosomiasis: Advances and failures
18. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
19. Practical guide for the treatment of leishmaniasis
20. Leishmaniasis
21. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies
22. Efficacy of a short course (10 days) of high-dose meglumine antimoniate with or without interferon-γ in treating cutaneous leishmaniasis in Guatemala
23. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10 years)
24. Acute pancreatitis with the administration of meglumine antimoniate for the treatment of visceral leishmaniasis
25. Amphotericin B versus sodium stibogluconate in first-line treatment of Indian kala-azar
26. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
27. Activity of liposomal amphotericin B (Am B isome) against Leishmania infantum and tissue distribution in mice
28. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial
29. Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)
30. Efficacy and tolerability of liposomal amphotericin B in Italian infants with visceral leishmaniasis
31. Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis
32. Treatment of visceral leishmaniasis in children with liposomal amphotericin B
33. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
34. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries
35. Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)
36. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion)
37. Treatment of kala-azar in Brazil with Amphocil® (amphotericin B cholesterol dispersion) for 5 days
38. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients
39. Short-course low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony
40. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis
41. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis
42. The sensitivity of Leishmania species to aminosidine
43. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis
44. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or in combined with sodium stibogluconate
45. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India
46. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia
47. Effect of treatment with interferon-γ alone in visceral leishmaniasis
48. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-γ
49. Miltefosine. The long-awaited therapy for visceral leishmaniasis?
50. Hexadecylphosphocoline: Oral treatment of visceral leishmaniasis in mice
51. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
52. Atovaquone alone or with fluconazole as oral therapy for Indian kala-azar
53. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy
54. Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum
55. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial
56. Failure of ketoconazole treatment in cutaneous leishmaniasis
57. Topical treatment of cutaneous leishmaniasis
58. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment
59. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran
60. Treatment of cutaneous leishmaniasis with nitric-oxide donor
61. A topical nitric oxide-generating therapy for cutaneous leishmaniasis
62. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy
63. Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1